Electrosynthesis of Co-ZIF Using Bio-Derived Solvents: Electrochemical Evaluation of Synthesised MOFs as a Binder-Free Supercapacitor Electrode in Alkaline Electrolyte

Supercapacitors hold promise for energy storage due to their exceptional power density and fast charge/discharge cycles. However, their performance hinges on the electrode material. Zeolitic imidazolate frameworks (ZIFs) are attractive options due to their tailorable structure and high surface area. But traditional ZIF synthesis relies on toxic solvents derived from fossil fuels, hindering their envisioned environmental benefit. This study explores using bio-derived solvents for a greener and potentially superior approach. The researchers employed anodic electrodeposition to synthesise cobalt-based ZIFs (Co-ZIFs) as supercapacitor electrode materials. Two linkers (2-methylimidazole and benzimidazole) and two bio-derived solvents (CyreneTM and γ-valerolactone (GVL)) were investigated. X-ray diffraction analysis revealed that bio-derived solvents enhanced the crystallinity of Co-ZIFs compared to traditional solvents. Notably, CyreneTM promoted better crystallinity for Co-bIM/Co-mIM structures. The Full Width at Half Maximum (FWHM) analysis suggests CyreneTM promotes Co-bIM/Co-mIM crystallinity (lower FWHM). Co-mIM in CyreneTM exhibits the best crystallinity (FWHM = 0.233) compared to other ZIF samples. Scanning electron microscopy confirmed these findings, showing larger and well-defined crystals for bio-derived solvent-synthesised ZIFs. The choice of solvent significantly impacted the final ZIF structure. While 2-methylimidazole consistently formed ZIF-67 regardless of the solvent, benzimidazole exhibited solvent-dependent behaviour. GVL yielded the highly porous Co-ZIF-12 structure, whereas DMF (N,N-dimethylformamide) and CyreneTM produced the less porous ZIF-9. This work reports the first-ever instance of ZIF-12 synthesis via an electrochemical method, highlighting the crucial interplay between solvent and precursor molecule in determining the final ZIF product. The synthesised binder-free Co-ZIF electrodes were evaluated for supercapacitor performance. The capacitance data revealed GVL as the most effective solvent, followed by DMF and then CyreneTM. This suggests GVL is the preferred choice for this reaction due to its superior performance. The ZIF-12-based electrode exhibits an impressive specific capacitance (Csp) of 44 F g⁻1, significantly higher than those achieved by ZIF-9-Cyrene (1.2 F g⁻1), ZIF-9-DMF (2.5 F g⁻1), ZIF-67-GVL (35 F g⁻1), ZIF-67-Cyrene (6 F g⁻1), and ZIF-67-DMF (16 F g⁻1) at 1 A g−1. This surpasses the Csp of all other ZIFs studied, including high-performing ZIF-67(GVL). ZIF-12(GVL) maintained superior Csp even at higher current densities, demonstrating exceptional rate capability. Among the bio-derived solvents, GVL outperformed CyreneTM. Notably, the Co-bIM in the GVL sample exhibited a ZIF-12-like structure, offering potential advantages due to its larger pores and potentially higher surface area compared to traditional ZIF-67 and ZIF-9 structures. This work presents a significant advancement in Co-ZIF synthesis. By utilising bio-derived solvents, it offers a more sustainable and potentially superior alternative. This paves the way for the eco-friendly production of Co-ZIFs with improved properties for supercapacitors, gas separation, catalysis, and other applications

Two Candidate High-Redshift X-ray Jets Without Coincident Radio Jets

We report the detection of extended X-ray emission from two high-redshift radio quasars. These quasars, J1405+0415 at $z$=3.208 and J1610+1811 at $z$=3.118, were observed in a Chandra snapshot survey selected from a complete sample of the radio-brightest quasars in the overlap area of the VLA-FIRST radio survey and the Sloan Digital Sky Survey. The extended X-ray emission is located along the line connecting the core to a radio knot or hotspot, favoring the interpretation of X-ray jets. The inferred rest frame jet X-ray luminosities from 2--30 keV would be of order 10$^{45}$ erg~s$^{-1}$ if emitted isotropically and without relativistic beaming. In the scenario of inverse Compton scattering of the cosmic microwave background (CMB), X-ray jets without a coincident radio counterpart may be common, and should be readily detectable to redshifts even beyond 3.2 due to the (1+$z$)$^4$ increase of the CMB energy density compensating for the (1+$z$)$^{-4}$ cosmological diminution of surface brightness. If these can be X-ray confirmed, they would be the second and third examples of quasar X-ray jets without detection of underlying continuous radio jets.Comment: 10 pages, 4 figures. Accepted for publication in The Astrophysical Journa

Genome-Wide Association Study Identifies First Locus Associated with Susceptibility to Cerebral Venous Thrombosis

Objective Cerebral venous thrombosis (CVT) is an uncommon form of stroke affecting mostly young individuals. Although genetic factors are thought to play a role in this cerebrovascular condition, its genetic etiology is not well understood. Methods A genome-wide association study was performed to identify genetic variants influencing susceptibility to CVT. A 2-stage genome-wide study was undertaken in 882 Europeans diagnosed with CVT and 1,205 ethnicity-matched control subjects divided into discovery and independent replication datasets. Results In the overall case-control cohort, we identified highly significant associations with 37 single nucleotide polymorphisms (SNPs) within the 9q34.2 region. The strongest association was with rs8176645 (combined p = 9.15 x 10(-24); odds ratio [OR] = 2.01, 95% confidence interval [CI] = 1.76-2.31). The discovery set findings were validated across an independent European cohort. Genetic risk score for this 9q34.2 region increases CVT risk by a pooled estimate OR = 2.65 (95% CI = 2.21-3.20, p = 2.00 x 10(-16)). SNPs within this region were in strong linkage disequilibrium (LD) with coding regions of the ABO gene. The ABO blood group was determined using allele combination of SNPs rs8176746 and rs8176645. Blood groups A, B, or AB, were at 2.85 times (95% CI = 2.32-3.52, p = 2.00 x 10(-16)) increased risk of CVT compared with individuals with blood group O. Interpretation We present the first chromosomal region to robustly associate with a genetic susceptibility to CVT. This region more than doubles the likelihood of CVT, a risk greater than any previously identified thrombophilia genetic risk marker. That the identified variant is in strong LD with the coding region of the ABO gene with differences in blood group prevalence provides important new insights into the pathophysiology of CVT. ANN NEUROL 2021Peer reviewe

Abstract 152: Genome-wide Association Study of Early-Onset Ischemic Stroke Identifies Novel Locus on Chromosome 12 Near BCL7A/MLXIP

Introduction: Genetic studies of early-onset disease have been an effective strategy to identify novel pathways and drug targets relevant to later-onset disease. Few studies have investigated the role of common genetic variation in the etiology of early-onset ischemic stroke (IS). Methods: We performed a GWAS meta-analysis of 38 studies from 10 countries, comprised of 5,847 IS cases of European ancestry under age 60 and 32,533 controls. Results: We identified two genome-wide significant (p< 5 x 10 -8 ) loci (see Figure). The ABO locus has previously been associated with venous thrombosis and ischemic stroke in predominantly older adults, but the effect size of our top SNP (OR 1.18; p = 9.1 x 10 -12 ) is larger than the effect size for this same SNP in MEGASTROKE (OR: 1.05; p = 6.5 x 10 -5 ). The lead SNP at the BCL7A/MLXIP locus is a novel GWAS finding for stroke (OR 1.14, 95% CI 1.08-1.19; p = 1.7 x 10 -8 ) and is noteworthy because of prior reports linking SNPs in these genes to BMI and blood pressure. Conclusions: We identified a novel locus that is near variants associated with BMI and blood pressure. Further studies are needed to confirm this locus, examine subtype specificity, and determine its function. The larger effect size observed at the ABO in this early-onset IS sample compared to older-onset IS samples is consistent with a larger role for prothrombotic mechanisms in early-onset IS

Genetic variants influencing elevated myeloperoxidase levels increase risk of stroke

Primary intracerebral haemorrhage and lacunar ischaemic stroke are acute manifestations of progressive cerebral microvascular disease. Current paradigms suggest atherosclerosis is a chronic, dynamic, inflammatory condition precipitated in response to endothelial injury from various environmental challenges. Myeloperoxidase plays a central role in initiation and progression of vascular inflammation, but prior studies linking myeloperoxidase with stroke risk have been inconclusive. We hypothesized that genetic determinants of myeloperoxidase levels influence the development of vascular instability, leading to increased primary intracerebral haemorrhage and lacunar stroke risk. We used a discovery cohort of 1409 primary intracerebral haemorrhage cases and 1624 controls from three studies, an extension cohort of 12 577 ischaemic stroke cases and 25 643 controls from NINDSSiGN, and a validation cohort of 10 307 ischaemic stroke cases and 29 326 controls from METASTROKE Consortium with genome-wide genotyping to test this hypothesis. A genetic risk score reflecting elevated myeloperoxidase levels was constructed from 15 common single nucleotide polymorphisms identified from prior genome-wide studies of circulating myeloperoxidase levels (P55 - 10 6). This genetic risk score was used as the independent variable in multivariable regression models for association with primary intracerebral haemorrhage and ischaemic stroke subtypes. We used fixed effects meta-analyses to pool estimates across studies. We also used Cox regression models in a prospective cohort of 174 primary intracerebral haemorrhage survivors for association with intracerebral haemorrhage recurrence. We present effects of myeloperoxidase elevating single nucleotide polymorphisms on stroke risk per risk allele, corresponding to a one allele increase in the myeloperoxidase increasing genetic risk score. Genetic determinants of elevated circulating myeloperoxidase levels were associated with both primary intracerebral haemorrhage risk (odds ratio, 1.07, P = 0.04) and recurrent intracerebral haemorrhage risk (hazards ratio, 1.45, P = 0.006). In analysis of ischaemic stroke subtypes, the myeloperoxidase increasing genetic risk score was strongly associated with lacunar subtype only (odds ratio, 1.05, P = 0.0012). These results, demonstrating that common genetic variants that increase myeloperoxidase levels increase risk of primary intracerebral haemorrhage and lacunar stroke, directly implicate the myeloperoxidase pathway in the pathogenesis of cerebral small vessel disease. Because genetic variants are not influenced by environmental exposures, these results provide new support for a causal rather than bystander role for myeloperoxidase in the progression of cerebrovascular disease. Furthermore, these results support a rationale for chronic inflammation as a potential modifiable stroke risk mechanism, and suggest that immune-targeted therapies could be useful for treatment and prevention of cerebrovascular disease

Age of onset of cerebral venous thrombosis: the BEAST study

Background: Cerebral venous thrombosis (CVT) is an uncommon cause of stroke in young adults. We aimed to determine the impact of age, gender and risk factors (including sex-specific) on CVT onset. Methods: We used data from the BEAST (Biorepository to Establish the Aetiology of Sinovenous Thrombosis), a multicentre multinational prospective observational study on CVT. Composite factors analysis (CFA) was performed to determine the impact on the age of CVT onset in males and females. Results: A total of 1309 CVT patients (75.3% females) aged ⩾18 years were recruited. The overall median (IQR-interquartile range) age for males and females was 46 (35–58) years and 37 (28–47) years (p < 0.001), respectively. However, the presence of antibiotic-requiring sepsis (p = 0.03, 95% CI 27–47 years) among males and gender-specific risk factors like pregnancy (p < 0.001, 95% CI 29–34 years), puerperium (p < 0.001, 95% CI 26–34 years) and oral contraceptive use (p < 0.001, 95% CI 33–36 years) were significantly associated with earlier onset of CVT among females. CFA demonstrated a significantly earlier onset of CVT in females, ~12 years younger, in those with multiple (⩾1) compared to ‘0’ risk factors (p < 0.001, 95% CI 32–35 years). Conclusions: Women suffer CVT 9 years earlier in comparison to men. Female patients with multiple (⩾1) risk factors suffer CVT ~12 years earlier compared to those with no identifiable risk factors

Genome-Wide Association Study Identifies First Locus Associated with Susceptibility to Cerebral Venous Thrombosis

Objective: Cerebral venous thrombosis (CVT) is an uncommon form of stroke affecting mostly young individuals. Although genetic factors are thought to play a role in this cerebrovascular condition, its genetic etiology is not well understood. Methods: A genome-wide association study was performed to identify genetic variants influencing susceptibility to CVT. A 2-stage genome-wide study was undertaken in 882 Europeans diagnosed with CVT and 1,205 ethnicity-matched control subjects divided into discovery and independent replication datasets. Results: In the overall case–control cohort, we identified highly significant associations with 37 single nucleotide polymorphisms (SNPs) within the 9q34.2 region. The strongest association was with rs8176645 (combined p = 9.15 × 10 −24; odds ratio [OR] = 2.01, 95% confidence interval [CI] = 1.76–2.31). The discovery set findings were validated across an independent European cohort. Genetic risk score for this 9q34.2 region increases CVT risk by a pooled estimate OR = 2.65 (95% CI = 2.21–3.20, p = 2.00 × 10 −16). SNPs within this region were in strong linkage disequilibrium (LD) with coding regions of the ABO gene. The ABO blood group was determined using allele combination of SNPs rs8176746 and rs8176645. Blood groups A, B, or AB, were at 2.85 times (95% CI = 2.32–3.52, p = 2.00 × 10 −16) increased risk of CVT compared with individuals with blood group O. Interpretation: We present the first chromosomal region to robustly associate with a genetic susceptibility to CVT. This region more than doubles the likelihood of CVT, a risk greater than any previously identified thrombophilia genetic risk marker. That the identified variant is in strong LD with the coding region of the ABO gene with differences in blood group prevalence provides important new insights into the pathophysiology of CVT. ANN NEUROL 2021;90:777–788

Genome-Wide Association Study Identifies First Locus Associated with Susceptibility to Cerebral Venous Thrombosis

Objective Cerebral venous thrombosis (CVT) is an uncommon form of stroke affecting mostly young individuals. Although genetic factors are thought to play a role in this cerebrovascular condition, its genetic etiology is not well understood. Methods A genome-wide association study was performed to identify genetic variants influencing susceptibility to CVT. A 2-stage genome-wide study was undertaken in 882 Europeans diagnosed with CVT and 1,205 ethnicity-matched control subjects divided into discovery and independent replication datasets. Results In the overall case-control cohort, we identified highly significant associations with 37 single nucleotide polymorphisms (SNPs) within the 9q34.2 region. The strongest association was with rs8176645 (combined p = 9.15 x 10(-24); odds ratio [OR] = 2.01, 95% confidence interval [CI] = 1.76-2.31). The discovery set findings were validated across an independent European cohort. Genetic risk score for this 9q34.2 region increases CVT risk by a pooled estimate OR = 2.65 (95% CI = 2.21-3.20, p = 2.00 x 10(-16)). SNPs within this region were in strong linkage disequilibrium (LD) with coding regions of the ABO gene. The ABO blood group was determined using allele combination of SNPs rs8176746 and rs8176645. Blood groups A, B, or AB, were at 2.85 times (95% CI = 2.32-3.52, p = 2.00 x 10(-16)) increased risk of CVT compared with individuals with blood group O. Interpretation We present the first chromosomal region to robustly associate with a genetic susceptibility to CVT. This region more than doubles the likelihood of CVT, a risk greater than any previously identified thrombophilia genetic risk marker. That the identified variant is in strong LD with the coding region of the ABO gene with differences in blood group prevalence provides important new insights into the pathophysiology of CVT. ANN NEUROL 202